StockNews.com 开始报道扩散制药（纳斯达克股票代码：DFFN）

Investment analysts at StockNews.com began coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research note issued on Monday. The firm set a "hold" rating on the stock.

Diffusion Pharmaceuticals Price Performance

DFFN opened at $6.21 on Monday. The stock's 50 day simple moving average is $5.93 and its 200 day simple moving average is $5.99. Diffusion Pharmaceuticals has a 1 year low of $4.64 and a 1 year high of $19.80. The firm has a market cap of $12.66 million, a price-to-earnings ratio of -0.81 and a beta of 1.82.

Get Diffusion Pharmaceuticals alerts:

Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($1.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.69. As a group, sell-side analysts anticipate that Diffusion Pharmaceuticals will post -8.04 EPS for the current year.

Institutional Investors Weigh In On Diffusion Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Trexquant Investment LP purchased a new stake in Diffusion Pharmaceuticals in the 2nd quarter worth approximately $71,000. Renaissance Technologies LLC lifted its holdings in Diffusion Pharmaceuticals by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company's stock worth $331,000 after buying an additional 101,100 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in Diffusion Pharmaceuticals in the 1st quarter worth approximately $106,000. Hedge funds and other institutional investors own 9.24% of the company's stock.

Diffusion Pharmaceuticals Company Profile

(Get Rating)

Diffusion Pharmaceuticals, Inc is a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia.

See Also

• Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
• Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
• MarketBeat Week in Review – 1/30 – 2/3
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.